Navigation Links
Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Date:11/3/2010

EAST HANOVER, N.J., Nov. 3, 2010 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS)(1,2). This study, which was previously presented at the 46th American Society of Clinical Oncology annual meeting, is the first prospective clinical trial of a drug to show treatment benefit in these patients.

Tuberous sclerosis is a genetic disorder that is estimated to affect 25,000 to 40,000 people in the US and may cause benign tumors to form in vital organs(3). SEGAs, benign brain tumors, occur in up to 20% of patients with TS and primarily affect children and adolescents(1,4,5). SEGAs may pose a significant medical risk, including the potential for swelling in the brain, or hydrocephalus(1).

According to data published in NEJM from this Phase I/II study of 28 patients conducted by Cincinnati Children's Hospital Medical Center, treatment with everolimus was associated with a significant reduction in primary SEGA volume at six months relative to baseline on independent central review (p<0.001). Seventy-five percent of patients (21 of 28) experienced a reduction of 30% or greater in the size of their largest SEGA and 32% (9 of 28) experienced a reduction of 50% or greater at six months relative to baseline(2).

The published study findings also showed that in nine of 16 patients, everolimus therapy was associated with a reduction from baseline to six months in overall frequency of seizures per 24 hour video electroencephalograms (EEG) (n=16; median change -1 seizure, p=0.022). Additionally, no patients required surgery or developed a new SEGA while receiving everolimus(2).

The most common adverse reactions observed (incidence greater than or equal to 30%) in this trial were mouth sores,
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- The management team at Columbia Laboratories, Inc. (Nasdaq: ... call on July 31, 2014, to discuss financial ... 2014.  The call details are as follows:Date: , ... numbers: , Toll free: (877) 870-4263 (U.S.), (855) ... , www.columbialabs.com , under ,Investor, or ...
(Date:7/23/2014)... SUNNYVALE, Calif. , July 23, 2014 /PRNewswire/ ... devices for the transcarotid treatment of intra- and ... Michael P. Wallace to the position ... Michael will lead the company,s Research and Development ... treatment devices. Prior to joining ...
(Date:7/23/2014)... July 23, 2014  Dompe, a leader in R&D for ... that rhNGF (Recombinant Human Nerve Growth Factor) has been designated ... Administration (FDA). The candidate drug, developed by ... drug for the treatment of neurotrophic keratitis, a degenerative corneal ... and is currently without a cure. This is the ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
... DIEGO, April 20, 2012 /PRNewswire-iReach/ -- Nutrilys ... San Diego, has partnered with the Los Angeles Police ... armor. Nutrilys Del Mar founder, Thierry Lerond, journeyed to Los ... while helping them handpick the world,s best organic, ...
... 2012  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, today announced that ... quarter of fiscal year 2012 on Tuesday, May 1. ... to discuss its financial results and operating activities, open ...
Cached Medicine Technology:Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit 2Thoratec Schedules First Quarter Conference Call, Webcast 2
(Date:7/23/2014)... TX (PRWEB) July 23, 2014 Texas ... seven physical therapists from their Westlake, Westgate, Liberty Hill, ... earned the professional designation of Orthopaedic Certified Specialist ... this June. Adriana Juarez, PT, DPT, OCS, Tony Lauretta, ... Milligan, PT, DPT, OCS, Joseph Leech, PT, DPT, OCS, ...
(Date:7/23/2014)... July 23, 2014 CarePoint Health is ... hospital in New Jersey to receive the da Vinci® ... platform in the da Vinci series. This 4th generation ... step forward in innovation. The intuitive da Vinci Xi ... wide spectrum of minimally invasive and complex surgical procedures. ...
(Date:7/23/2014)... July 23, 2014 Recently, Agebc.com has ... Now, the company is announcing a promotion of wedding ... promotion will end at the end of this month. ... many popular styles, like A-line, mermaid, ball-gown, empire, and ... dresses and other special-occasion dresses for women, and the ...
(Date:7/23/2014)... In its latest blog post, Best ... having family close by during a stay in rehab can ... is successful, is focusing on a topic that is quickly ... dialogues: opiate abuse facts. , The Best Drug Rehabilitation blog ... An overview of opiates, and why they’re considered “the mother ...
(Date:7/23/2014)... Europe Drilling fluid and Completion fluid Market Report defines and ... with analysis and forecast of revenue. The drilling fluid and ... around $1.3 billion in 2013 to $1.7 billion by 2018, ... Browse through the TOC of the Europe drilling fluid and ... in-depth analysis provided. This also provides a glimpse of the ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 2Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 3Health News:CarePoint Health is First in New Jersey to Receive Newest Surgical Robot Platform 4Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 5Health News:Europe Drilling Fluid & Completion Fluid Market is Expected to Reach $1.7 Billion in 2018 - New Report by MicroMarket Monitor 6
... is widely accepted that urgent endoscopy for UGIB should be performed ... time, it is still unclear whether it should be performed either ... more delayed interval, such as after 6, 12 or 24 hour. ... been yet established. , A research article to be published on ...
... Brazos Valley residents,neuroscience researchers, and interested clinicians will ... on the,topic of stroke during the Texas Brain ... 19. This year,s symposium will consist of a,morning ... for clinicians,and researchers. The speakers are both neuroscience ...
... Dialysis Providers, Patient Advocates Work with Local Kidney,Community ... Texas, Sept. 9 With the,highest per capita ... the,Gulf Coast region is bracing to avoid a ... disrupt the administration of,life-saving dialysis treatments to area ...
... 9 Encorium Group, Inc.,(Nasdaq: ENCO ), ... studies in over 30 countries for many of ... that it,has entered into an amendment (the "Amendment") ... Inc. ("Prologue"). Pursuant to the,Amendment, the Company will ...
... Correction of Familial Risk Estimates Increases Estimated Melanoma Risk ... The relative risk of familial melanoma increases substantially when ... large cohort study. The relative risk of familial lung, ... with the correction. , Researchers have used the Swedish ...
... in the United States undergo lung surgery each year, ... their care. In the current issue of The ... proposed a system of lung surgery quality indicators for ... best practices for obtaining positive patient outcomes. , Death ...
Cached Medicine News:Health News:Texas Brain and Spine Institute to Hold Second Annual Neuroscience Symposium 2Health News:Gulf Coast Dialysis Caregivers, Volunteers Brace for Hurricane Ike; Prepare to Maintain Power, Continued Access for Patients to Life-Saving Treatment 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 2Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 3Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 4Health News:Prologue Acquisition Update and Termination of Linkcon Business Combination 5Health News:Also in the Sept. 9 JNCI 2Health News:Also in the Sept. 9 JNCI 3Health News:Mayo Clinic chest surgeons propose measures for indicating quality of lung surgery 2Health News:Mayo Clinic chest surgeons propose measures for indicating quality of lung surgery 3
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
Medicine Products: